top-line results showed that the primary endpoint of non-inferiority was met with a difference of -1.8 between the two therapies with variability between -8.2 and 3.1 (90% confidence limit).

In clinical studies with Propecia (finasteride, 1 mg) in men 18-41 years of age, the mean value of serum prostate-specific antigen (PSA) decreased from 0.7 ng/ml at baseline to 0.5 ng/ml at month 12.